 neutral broad updat across
messag report financi result broad array clinic
updat across pipelin margetuximab remain track read next interim
analysi submit potenti bla breast cancer initi
registr phase trial mahogani gastric cancer franchis
remain track enoblituzumab initi phase fda meet
 bispecif pivot combin studi inhibitor
line prior guidanc flotetuzumab updat initi
expans cohort inhibitor updat estim reflect result
remain neutral rate stock pleas also see initi sinc
believ margetuximab commerci potenti breast gastric cancer
modest given competitor antibody-drug conjug dsnky/
azn read compel data similar patient popul similarli think
 bispecif flotetuzumab may enter moder size market aml
could potenti becom crowd given sever competitor bispecif
antibody-drug conjug target cytotoxin car-t therapi develop
agent enoblituzumab view modest singl agent activ
contribut toward combin unclear poc readout given
orr post-checkpoint inhibitor patient
sophia read second interim os data potenti submit bla
follow sophia readout link compani expect read
next interim os analysi event near year-end potenti san
antonio breast cancer symposium interim analysi includ
potenti margetuximab bla file expect around time compani
expect analyz final os dataset event sometim
track initi phase mahogani trial margetuximab
checkpoint inhibitor cpi gastric cancer mgc trial consist
modul modul consist singl arm cohort margetuximab
potenti acceler approv base orr endpoint patient
compani hope surpass orr achiev trastuzumab chemo
phase toga trial phase ii portion modul modul
four arm compar margetuximab chemo checkpoint inhibitor either
 bispecif standard care trastuzumab chemo
meantim provid updat surviv data phase gastric cancer
studi combin pembrolizumab esmo see planner note
studi previous read month mo mgc mo reach
dual patient
increas competit mgc though could establish nich
dual patient given respons observ phase monotherapi
mgc could potenti face competit headwind emerg
agent dsnky/azn achiev orr month mpf
month mo link heavily-pretr patient popul median prior
line well bispecif zyme/bgn read earli
promis orr singl agent gastric cancer patient
eortc-nci-aacr meet said regimen also select pd-
posit potenti mgc patient per management comment
advanc phase portion mahogani modul data
phase basket studi read report tumor type includ mgc
page analyst certif import disclosur
franchis track enoblituzumab initi registr phase studi
head neck cancer patient sometim compani recent met fda
establish registr pathway enoblituzumab initi phase
studi combin furthermor develop priorit
develop combin note previous partial
clinic hold sinc resolv single-ag due potenti cytokin release-
relat toxic recent report patient death studi combin
inhibitor t-cell engag
flotetuzumab bispecif data updat acut
myeloid leukemia aml combin studi inhibitor initi
request end phase meet fda hope conduct
establish potenti path registr
 bispecif data readout guid earli
compani finish enrol phase expans cohort
patient provid clinic updat compani previous
mention potenti issu on-target toxic program
updat estim reflect result adjust flotetuzumab estim
account termin partnership agreement servier well enoblituzumab
estim account i-mab partnership greater china maintain neutral
page analyst certif import disclosur
valuat risk
valu use discount cash flow analysi use
wacc consist clinical-stag biotech compani cover
proof-of-concept data well termin growth rate downsid risk includ
 regulatori commerci setback potenti emerg new competitor
lower product sale expect upsid risk includ higher product sale
expect pipelin success beyond alreadi account forecast
potenti acquisit premium current valuat
page analyst certif import disclosur
total cost expens
interest incom net
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
